LRRK2 and Parkinson disease: Indeed, LRRK2 inhibitors remain an exciting therapeutic prospect for PD and it may be of interest to determine if any phenotypes in the Lrrk2 S910A/S935A knockin mice can be reversed with inhibitor treatment.